Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose booster COVID-19 mRNA vaccine study in recovered patients
ChiCTR2200061478Phase 2Recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Jun 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of RH109 in coronavirus disease 2019 (COVID-19) (8 arms), sponsored by Shanghai East Hospital. Primary endpoints: Spike protein binding antibody titer, Pseudovirus neutralization antibody titer and 1 more. Started Jun 2022; status: recruiting.
02
Drugs
RH109
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200061478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061478.